Advertisement

Irish Journal of Medical Science

, Volume 180, Issue 2, pp 521–527 | Cite as

Diet, obesity and cancer

  • J. V. Reynolds
  • C. L. Donohoe
  • S. L. Doyle
Invited Commentary

Abstract

Introduction and aims

Obesity and the rising incidence of certain cancers are the manifest expressions of problems with diet and lifestyle. A number of complex and closely inter-related factors mediate the association between environment and cancer development. This review seeks to summarise the current evidence pertaining to dietary factors and cancer incidence and progression.

Methods

Relevant literature was identified by search of the Pubmed database using the terms: diet, cancer, carcinogenesis, tumourigenesis. References from relevant articles were searched. Selection of articles was based on peer review, journal and relevance. Where possible, meta-analyses of randomised controlled trials (RCTs) or large RCTs were cited preferentially.

Results

Variations in cancer trends between geographic regions and in migration studies point to the key role of environmental differences in cancer incidence. Mechanisms of tumorigenesis, including inflammation, angiogenesis, may be influenced by specific dietary constituents including glucosinolates, organosulphur compounds, genistein, curcumin, catechins, resveratrol and lycopene.

Conclusion

Despite epidemiological evidence suggesting a link between dietary factors and cancer development, confounding factors such as obesity, physical activity and the sheer variety of bioactive compounds in a normal diet pose a great challenge to the study of mechanisms linking diet and cancer. A greater understanding of the interplay between dietary constituents and cancer development should un-cover new targets for the prevention and treatment of cancer.

Keywords

Diet Obesity Cancer Visceral adiposity Curcumin Angiogenesis Inflammation Phytochemicals Catechins Genistein Lycopene 

References

  1. 1.
    Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880PubMedCrossRefGoogle Scholar
  2. 2.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRefGoogle Scholar
  3. 3.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578PubMedCrossRefGoogle Scholar
  4. 4.
    Morgan KMH, Watson D, Perry I et al (2008) SLAN 2007: survey of lifestyle, attitudes and nutrition in Ireland. Department of Health and Children, DublinGoogle Scholar
  5. 5.
    Fund WCR (2007) Food, nutrition, physical activity and the prevention of cancer: a global perspective, 2nd edn. American Institute for Cancer Research, WashingtonGoogle Scholar
  6. 6.
    (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894(i–xii):1–253Google Scholar
  7. 7.
    Surh Y-J (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768–780PubMedCrossRefGoogle Scholar
  8. 8.
    Folkman J, Hochberg M (1973) Self-regulation of growth in three dimensions. J Exp Med 138:745–753PubMedCrossRefGoogle Scholar
  9. 9.
    Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739PubMedCrossRefGoogle Scholar
  10. 10.
    Folkman J, Kalluri R (2004) Cancer without disease. Nature 427:787PubMedCrossRefGoogle Scholar
  11. 11.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedCrossRefGoogle Scholar
  12. 12.
    Cao Y, Cao R, Brakenhielm E (2002) Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 13:380–390PubMedCrossRefGoogle Scholar
  13. 13.
    Singh RP, Agarwal R (2003) Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 3:205–217PubMedCrossRefGoogle Scholar
  14. 14.
    Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98–101PubMedGoogle Scholar
  15. 15.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRefGoogle Scholar
  16. 16.
    Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645Google Scholar
  17. 17.
    Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522PubMedCrossRefGoogle Scholar
  18. 18.
    Barnes PJ, Karin M (1997) Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071PubMedCrossRefGoogle Scholar
  19. 19.
    Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC (2003) Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 54:131–152PubMedCrossRefGoogle Scholar
  20. 20.
    Hatcher H, Planalp R, Cho J, Torti F, Torti S (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631–1652PubMedCrossRefGoogle Scholar
  21. 21.
    Azuine MA, Kayal JJ, Bhide SV (1992) Protective role of aqueous turmeric extract against mutagenicity of direct-acting carcinogens as well as benzo [alpha] pyrene-induced genotoxicity and carcinogenicity. J Cancer Res Clin Oncol 118:447–452PubMedCrossRefGoogle Scholar
  22. 22.
    Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer, base no. 5, version 2.0. IARC Press, LyonGoogle Scholar
  23. 23.
    López-Lázaro M (2008) Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52:S103–S127PubMedGoogle Scholar
  24. 24.
    Shishodia S, Singh T, Chaturvedi MM (2007) Modulation of transcription factors by curcumin. In: The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol 595:127–148Google Scholar
  25. 25.
    Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787–809PubMedCrossRefGoogle Scholar
  26. 26.
    Cheng AL, Hsu CH, Lin JK et al (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895–2900PubMedGoogle Scholar
  27. 27.
    Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–4499PubMedCrossRefGoogle Scholar
  28. 28.
    McKay DL, Blumberg JB (2002) The role of tea in human health: an update. J Am Coll Nutr 21:1–13PubMedGoogle Scholar
  29. 29.
    Liao S (2001) The medicinal action of androgens and green tea epigallocatechin gallate. Hong Kong Med J 7:369–374PubMedGoogle Scholar
  30. 30.
    Cabrera C, Artacho R, Gimenez R (2006) Beneficial effects of green tea—a review. J Am Coll Nutr 25:79–99PubMedGoogle Scholar
  31. 31.
    Gary DS, Hasan M (1995) Polyphenols as cancer chemopreventive agents. J Cell Biochem 59:169–180CrossRefGoogle Scholar
  32. 32.
    Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66:1234–1240PubMedCrossRefGoogle Scholar
  33. 33.
    McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA (2009) Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila PA) 2:673–682Google Scholar
  34. 34.
    Shimizu M, Fukutomi Y, Ninomiya M et al (2008) Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prevent 17:3020–3025CrossRefGoogle Scholar
  35. 35.
    Clarke JD, Dashwood RH, Ho E (2008) Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269:291–304PubMedCrossRefGoogle Scholar
  36. 36.
    Kjaerheim K, Gaard M, Andersen A (1998) The role of alcohol, tobacco, and dietary factors in upper aerogastric tract cancers: a prospective study of 10,900 Norwegian men. Cancer Causes Control 9:99–108PubMedCrossRefGoogle Scholar
  37. 37.
    Shukla Y, Kalra N (2007) Cancer chemoprevention with garlic and its constituents. Cancer Lett 247:167–181PubMedCrossRefGoogle Scholar
  38. 38.
    Graham DY, Anderson SY, Lang T (1999) Garlic or jalapeno peppers for treatment of Helicobacter pylori infection. Am J Gastroenterol 94:1200–1202PubMedGoogle Scholar
  39. 39.
    Iimuro M, Shibata H, Kawamori T et al (2002) Suppressive effects of garlic extract on Helicobacter pylori-induced gastritis in Mongolian gerbils. Cancer Lett 187:61–68PubMedCrossRefGoogle Scholar
  40. 40.
    Hu J, Nyren O, Wolk A et al (1994) Risk factors for oesophageal cancer in northeast China. Int J Cancer 57:38–46PubMedCrossRefGoogle Scholar
  41. 41.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 54:2390–2397PubMedGoogle Scholar
  42. 42.
    Steinmetz KA, Kushi LH, Bostick RM, Folsom AR, Potter JD (1994) Vegetables, fruit, and colon cancer in the Iowa Women’s Health Study. Am J Epidemiol 139:1–15PubMedGoogle Scholar
  43. 43.
    Hsing AW, Chokkalingam AP, Gao YT et al (2002) Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst 94:1648–1651PubMedGoogle Scholar
  44. 44.
    Banerjee S, Li Y, Wang Z, Sarkar FH (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett 269:226–242PubMedCrossRefGoogle Scholar
  45. 45.
    Yanagihara K, Ito A, Toge T, Numoto M (1993) Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 53:5815–5821PubMedGoogle Scholar
  46. 46.
    Mukhopadhyay S, Ballard BR, Mukherjee S, Kabir SM, Das SK (2006) Beneficial effects of soy protein in the initiation and progression against dimethylbenz [a] anthracene-induced breast tumors in female rats. Mol Cell Biochem 290:169–176PubMedCrossRefGoogle Scholar
  47. 47.
    Kobayashi T, Nakata T, Kuzumaki T (2002) Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 176:17–23PubMedCrossRefGoogle Scholar
  48. 48.
    Gossner G, Choi M, Tan L et al (2007) Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol 105:23–30PubMedCrossRefGoogle Scholar
  49. 49.
    Farina HG, Pomies M, Alonso DF, Gomez DE (2006) Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 16:885–891PubMedGoogle Scholar
  50. 50.
    Messina MJ, Persky V, Setchell KD, Barnes S (1994) Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21:113–131PubMedCrossRefGoogle Scholar
  51. 51.
    Tatsuta M, Iishi H, Baba M, Yano H, Uehara H, Nakaizumi A (1999) Attenuation by genistein of sodium-chloride-enhanced gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer 80:396–399PubMedCrossRefGoogle Scholar
  52. 52.
    Williner MR, Pirovani ME, Güemes DR (2003) Ellagic acid content in strawberries. J Sci Food Agric 83:842–845CrossRefGoogle Scholar
  53. 53.
    Festa F, Aglitti T, Duranti G, Ricordy R, Perticone P, Cozzi R (2001) Strong antioxidant activity of ellagic acid in mammalian cells in vitro revealed by the Comet assay. Anticancer Res 21:3903–3908PubMedGoogle Scholar
  54. 54.
    Wedge DE, Meepagala KM, Magee JB, Smith SH, Huang G, Larcom LL (2001) Short communication: anticarcinogenic activity of strawberry, blueberry, and raspberry extracts to breast and cervical cancer cells. J Med Food 4:49–51PubMedCrossRefGoogle Scholar
  55. 55.
    Edderkaoui M, Odinokova I, Ohno I et al (2008) Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol 14:3672–3680PubMedCrossRefGoogle Scholar
  56. 56.
    Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G (2005) Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 47:449–455PubMedCrossRefGoogle Scholar
  57. 57.
    Janick J (2005) Origins of fruits, fruit growing, and fruit breeding. Plant Breed Rev 25:255–320Google Scholar
  58. 58.
    Loza-Tavera H (1999) Monoterpenes in essential oils. Biosynthesis and properties. Adv Exp Med Biol 464:49–62PubMedGoogle Scholar
  59. 59.
    Bardon S, Picard K, Martel P (1998) Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 32:1–7PubMedCrossRefGoogle Scholar
  60. 60.
    Wagner KH, Elmadfa I (2003) Biological relevance of terpenoids Overview focusing on mono-, di- and tetraterpenes. Ann Nutr Metab 47:95–106PubMedCrossRefGoogle Scholar
  61. 61.
    Elegbede JA, Elson CE, Qureshi A, Tanner MA, Gould MN (1984) Inhibition of DMBA‐induced mammary cancer by the monoterpene d‐limonene. Carcinogenesis 5:661–664Google Scholar
  62. 62.
    Haag JD, Gould MN (1994) Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemo Pharmacol 34:477–483Google Scholar
  63. 63.
    Kris‐Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE, Etherton TD (2002) Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 113:71–88Google Scholar
  64. 64.
    Rabi T, Bishayee A (2009) Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat 115:223–239PubMedCrossRefGoogle Scholar
  65. 65.
    Tapiero H, Townsend DM, Tew KD (2004) The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother 58:100–110PubMedCrossRefGoogle Scholar
  66. 66.
    Dorjgochoo T, Gao YT, Chow WH et al (2009) Plasma carotenoids, tocopherols, retinol and breast cancer risk: results from the Shanghai Women Health Study (SWHS). Breast Cancer Res Treat 117:381–389PubMedCrossRefGoogle Scholar
  67. 67.
    Van Patten CL, de Boer JG, Tomlinson Guns ES (2008) Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. J Urol 180:2314–2321; discussion 721–722Google Scholar
  68. 68.
    Haseen F, Cantwell MM, O’Sullivan JM, Murray LJ (2009) Is there a benefit from lycopene supplementation in men with prostate cancer. A systematic review. Pros Cancer Pros Dis 12:325–332CrossRefGoogle Scholar
  69. 69.
    Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523–1526PubMedCrossRefGoogle Scholar
  70. 70.
    Liu BL, Zhang X, Zhang W, Zhen HN (2007) New enlightenment of French Paradox: resveratrol’s potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther 6:1833–1836PubMedCrossRefGoogle Scholar
  71. 71.
    Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506PubMedCrossRefGoogle Scholar
  72. 72.
    Doll R, Hill AB (2004) The mortality of doctors in relation to their smoking habits: a preliminary report. 1954 BMJ 2004;328:1529–1533; discussion 33Google Scholar
  73. 73.
    Lynch LA, O’Connell JM, Kwasnik AK, Cawood TJ, O’Farrelly C, O’Shea DB (2009) Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 17:601–605CrossRefGoogle Scholar
  74. 74.
    O’Shea D, Cawood TJ, O’Farrelly C, Lynch L (2010) Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS One 5:e8660PubMedCrossRefGoogle Scholar
  75. 75.
    Howard JM, Pidgeon GP, Reynolds JV (2010) Leptin and gastro-intestinal malignancies. Obes Rev 11(12):863–874. doi: 10.1111/j.1467-789X.2010.00718.x Google Scholar
  76. 76.
    Doyle SL, Lysaght J, Reynolds JV (2009) Obesity and post-operative complications in patients undergoing non-bariatric surgery. Obes Rev 11(12):875–886Google Scholar
  77. 77.
    Healy LA, Ryan AM, Rowley S et al (2009) Obesity increases the risk of postmenopausal breast cancer and is associated with more advanced stage at presentation but no impact on survival. Breast J 25(11):1293–1299Google Scholar
  78. 78.
    Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV (2010) Obesity and gastrointestinal cancer. Br J Surg 97:628–642PubMedCrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2010

Authors and Affiliations

  1. 1.Department of SurgeryTrinity Centre for Health Sciences, Trinity College Dublin/St. James’ HospitalDublin 8Ireland

Personalised recommendations